A surge of a neural-specific protein in the brain is the earliest-yet biomarker for Alzheimer’s disease, report researchers studying a mouse model of the disease. Furthermore, the increased protein activity leads to the seizures associated with the earliest stages of neurodegeneration, and inhibiting the protein in the mice slowed the onset and progression of seizure activity. The neural-specific protein, PSD-95, could pose a new target for Alzheimer’s research, early diagnosis and treatment.
